Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M90,629Revenue $M19,960Net Margin (%)8.9Z-Score4.3
Enterprise Value $M96,635EPS $1.1Operating Margin %17.1F-Score6
P/E(ttm))24.6Cash Flow Per Share $0Pre-tax Margin (%)11.9Higher ROA y-yN
Price/Book19.310-y EBITDA Growth Rate %0Quick Ratio2.5Cash flow > EarningsY
Price/Sales4.55-y EBITDA Growth Rate %0Current Ratio2.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-14.1ROA % (ttm)7.4Higher Current Ratio y-yY
Dividend Yield %2.9Insider Buy (3m)0ROE % (ttm)47.0Less Shares Outstanding y-yN
Payout Ratio %151Shares Outstanding M1,593ROI % (ttm)22.2Gross Margin Increase y-yY

Gurus Latest Trades with ABBV

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ABBVJean-Marie Eveillard 2014-12-31 Buy 0.16%$52.9 - $69.71
($63.09)
$ 56.86-10%New holding, 1016097 sh.1,016,097
ABBVMario Gabelli 2014-12-31 Add0.01%$52.9 - $69.71
($63.09)
$ 56.86-10%Add 232.85%34,557
ABBVLee Ainslie 2014-12-31 Sold Out -4%$52.9 - $69.71
($63.24)
$ 56.86-10%Sold Out0
ABBVJohn Paulson 2014-12-31 Sold Out -3.1%$52.9 - $69.71
($63.24)
$ 56.86-10%Sold Out0
ABBVAndreas Halvorsen 2014-12-31 Sold Out -2.5%$52.9 - $69.71
($63.24)
$ 56.86-10%Sold Out0
ABBVSteve Mandel 2014-12-31 Sold Out -1.2%$52.9 - $69.71
($63.24)
$ 56.86-10%Sold Out0
ABBVGeorge Soros 2014-12-31 Sold Out -0.66%$52.9 - $69.71
($63.24)
$ 56.86-10%Sold Out0
ABBVJohn Paulson 2014-09-30 Buy 3.1%$52.05 - $59.62
($55.51)
$ 56.862%New holding, 13000000 sh.13,000,000
ABBVAndreas Halvorsen 2014-09-30 Buy 2.5%$52.05 - $59.62
($55.51)
$ 56.862%New holding, 10769105 sh.10,769,105
ABBVLee Ainslie 2014-09-30 Add1.26%$52.05 - $59.62
($55.51)
$ 56.862%Add 46.01%4,723,578
ABBVSteve Mandel 2014-09-30 Buy 1.2%$52.05 - $59.62
($55.51)
$ 56.862%New holding, 5247201 sh.5,247,201
ABBVGeorge Soros 2014-09-30 Add0.6%$52.05 - $59.62
($55.51)
$ 56.862%Add 924.76%1,537,146
ABBVJohn Hussman 2014-09-30 Reduce-0.87%$52.05 - $59.62
($55.51)
$ 56.862%Reduce -66.67%100,000
ABBVJoel Greenblatt 2014-09-30 Reduce-0.06%$52.05 - $59.62
($55.51)
$ 56.862%Reduce -89.36%9,460
ABBVLee Ainslie 2014-06-30 Buy 2.6%$46.46 - $56.79
($52.4)
$ 56.868%New holding, 3235133 sh.3,235,133
ABBVKen Fisher 2014-06-30 Add0.06%$46.46 - $56.79
($52.4)
$ 56.868%Add 76.13%1,104,609
ABBVNWQ Managers 2014-06-30 Buy 0.05%$46.46 - $56.79
($52.4)
$ 56.868%New holding, 83878 sh.83,878
ABBVJoel Greenblatt 2014-06-30 Reduce-0.11%$46.46 - $56.79
($52.4)
$ 56.868%Reduce -61.19%88,923
ABBVGeorge Soros 2014-06-30 Reduce-0.1%$46.46 - $56.79
($52.4)
$ 56.868%Reduce -57.14%150,000
ABBVJoel Greenblatt 2014-03-31 Add0.1%$46.83 - $53.68
($50.6)
$ 56.8612%Add 120.38%229,149
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ABBV is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ABBV Jean-Marie Eveillard 2014-12-311,016,0970.060.16New Buy
ABBV Mario Gabelli 2014-12-3134,55700.01+232.85%
ABBV NWQ Managers 2014-12-3196,0150.010.08+11.71%
ABBV PRIMECAP Management 2014-12-316,578,8860.410.44+1.92%
ABBV Robert Bruce 2014-12-31232,9150.014.2+0.7%
ABBV Ken Fisher 2014-12-311,001,1050.060.14+0.13%
ABBV John Hussman 2014-12-31100,0000.010.65
ABBV Dodge & Cox 2014-12-3138,05500-2.04%
ABBV Joel Greenblatt 2014-12-318,75900-7.41%
ABBV Steve Mandel 2014-12-31000Sold Out
ABBV Lee Ainslie 2014-12-31000Sold Out
ABBV Andreas Halvorsen 2014-12-31000Sold Out
ABBV John Paulson 2014-12-31000Sold Out
ABBV George Soros 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ABBV: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC 2015-03-02Sell25,000$60.3-0.05view
RICHMOND TIMOTHY J.SVP, Human Resources 2015-03-02Sell14,388$60.33-0.1view
SALEKI-GERHARDT AZITASVP, Operations 2015-02-27Sell2,112$60.47-0.33view
HURWICH THOMAS A.VP, Controller 2015-02-27Sell1,185$60.57-0.5view
RICHMOND TIMOTHY J.SVP, Human Resources 2015-02-17Sell241$58.72.67view
CHASE WILLIAM JEVP, CFO 2014-12-22Sell8,495$68-11.37view
HURWICH THOMAS A.VP, Controller 2014-11-24Sell1,500$67.81-11.12view
GONZALEZ RICHARD AChairman of the Board and CEO 2014-03-04Sell4,799$51.217.71view
ALBAN CARLOSEVP, Commercial Operations 2014-03-03Sell2,882$50.0920.32view
CHASE WILLIAM JEVP, CFO 2014-03-03Sell3,948$50.2220.01view

Press Releases about ABBV :

    Quarterly/Annual Reports about ABBV:

    News about ABBV:

    Articles On GuruFocus.com
    Cracking The Best Healthcare Dividend Stock Secrets Mar 02 2015 
    Dogs Of The S&P 500 - No Dividend Alternatives Are Cheaper! Feb 21 2015 
    Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
    Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
    Gilead Sciences Falls 10% After More Than Doubling Drug Discounts For 2015 Feb 05 2015 
    The Gabelli ABC Fund Merger and Arbitrage – “The Deal Fund” Q4 Commentary Feb 04 2015 
    AbbVie’s Q4 Reflects Its Tremendous Growth Potential Going Forward Feb 04 2015 
    Looking Ahead of Wall Street: Gilead Sciences, Chipotle, Twitter Feb 03 2015 
    Google Joins Biogen In The Fight Against Multiple Sclerosis Jan 29 2015 
    What Could Be The Major Highlights In AbbVie’s Upcoming Earnings Call? Jan 29 2015 

    More From Other Websites
    AbbVie to Buy Pharmacyclics to Expand In Cancer Therapy Mar 04 2015
    AbbVie to Buy Pharmacyclics in $21 Billion Deal Mar 04 2015
    Abbvie To Pay $21 Billion For Cancer Biotech Pharmacyclics Mar 04 2015
    AbbVie to buy Pharmacyclics in $21 billion deal Mar 04 2015
    Gilead Sciences: Harvoni Launch 'Off to a Strong Start' Mar 04 2015
    Analysts' Actions: AbbVie, Stratasys and More Mar 04 2015
    FDA Warns on Low-Testosterone Drugs Mar 03 2015
    FDA warning: men's testosterone drugs overused Mar 03 2015
    Why MannKind Could Lose Half Its Value Mar 03 2015
    Amgen Biosimilar Rheumatoid Arthritis Therapy Shows Positive Results Mar 01 2015
    Doctor Panel to Weigh Hepatitis C Drugs’ Costs in Guidelines Feb 27 2015
    ABBVIE INC. Financials Feb 27 2015
    AbbVie's HUMIRA® (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With... Feb 27 2015
    AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy... Feb 26 2015
    AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy... Feb 26 2015
    Health Care Stocks Flexing Their Muscle Feb 26 2015
    Cyberonics Soars On Earnings Beat, Tax Inversion Deal Feb 26 2015
    6 reasons biotech stocks may soon tank Feb 26 2015
    AbbVie Launches SigueElGuion.com to Educate Spanish-Speaking Americans about Hypothyroidism and the... Feb 26 2015
    AbbVie Launches SigueElGuion.com to Educate Spanish-Speaking Americans about Hypothyroidism and the... Feb 26 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK